IRIS
BRUNETTI, ORONZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.968
AS - Asia 1.358
EU - Europa 773
SA - Sud America 327
AF - Africa 41
OC - Oceania 3
AN - Antartide 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.472
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.926
SG - Singapore 569
CN - Cina 310
BR - Brasile 284
SE - Svezia 224
HK - Hong Kong 198
RU - Federazione Russa 154
VN - Vietnam 116
DE - Germania 80
GB - Regno Unito 69
IT - Italia 65
FR - Francia 49
IN - India 41
FI - Finlandia 36
BE - Belgio 25
ID - Indonesia 25
CA - Canada 24
AR - Argentina 22
PL - Polonia 16
CI - Costa d'Avorio 15
TR - Turchia 13
BD - Bangladesh 10
MX - Messico 10
CZ - Repubblica Ceca 9
JP - Giappone 9
UA - Ucraina 9
ZA - Sudafrica 9
ES - Italia 8
AE - Emirati Arabi Uniti 7
PK - Pakistan 7
EC - Ecuador 6
IR - Iran 6
IQ - Iraq 5
VE - Venezuela 5
AT - Austria 4
IL - Israele 4
KR - Corea 4
MA - Marocco 4
NL - Olanda 4
NP - Nepal 4
PY - Paraguay 4
SA - Arabia Saudita 4
UZ - Uzbekistan 4
AU - Australia 3
CH - Svizzera 3
CO - Colombia 3
IE - Irlanda 3
JO - Giordania 3
KE - Kenya 3
KZ - Kazakistan 3
AO - Angola 2
AZ - Azerbaigian 2
BH - Bahrain 2
CR - Costa Rica 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EG - Egitto 2
ET - Etiopia 2
JM - Giamaica 2
KW - Kuwait 2
LT - Lituania 2
QA - Qatar 2
RS - Serbia 2
TN - Tunisia 2
AL - Albania 1
AQ - Antartide 1
BB - Barbados 1
BG - Bulgaria 1
BJ - Benin 1
BO - Bolivia 1
BY - Bielorussia 1
CL - Cile 1
GE - Georgia 1
HN - Honduras 1
HR - Croazia 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LU - Lussemburgo 1
MM - Myanmar 1
MT - Malta 1
NO - Norvegia 1
PE - Perù 1
PH - Filippine 1
PS - Palestinian Territory 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TG - Togo 1
TH - Thailandia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.472
Salva come PNG Salva come JPEG
Città #
Fairfield 519
Ashburn 461
Chandler 443
Singapore 300
Woodbridge 282
Seattle 251
Cambridge 220
Houston 213
Hong Kong 194
Nyköping 182
Wilmington 170
Beijing 110
Ann Arbor 108
Dearborn 103
Dallas 69
New York 64
Lawrence 57
Roxbury 55
Los Angeles 45
Munich 41
Brooklyn 37
Des Moines 35
Ho Chi Minh City 35
São Paulo 30
Nanjing 29
The Dalles 28
Boardman 27
San Diego 25
Brussels 24
Dong Ket 24
Moscow 24
Columbus 22
Jakarta 21
Bari 19
Santa Clara 19
Turku 19
Council Bluffs 18
Hanoi 18
Paris 17
Abidjan 15
Inglewood 15
San Jose 15
Hefei 14
Chennai 13
Pune 13
Warsaw 13
Helsinki 12
London 11
Phoenix 11
Buffalo 10
Da Nang 10
Marseille 10
Montreal 10
Shanghai 10
Chicago 9
Stockholm 9
Tokyo 9
Denver 8
Frankfurt am Main 8
Guangzhou 8
Jinan 8
Orem 8
San Mateo 8
Düsseldorf 7
Manchester 7
Nuremberg 7
Poplar 7
Rio de Janeiro 7
Augusta 6
Belo Horizonte 6
Brno 6
Campinas 6
Curitiba 6
Edinburgh 6
Jacksonville 6
Johannesburg 6
San Francisco 6
Atlanta 5
Blumenau 5
Kilburn 5
Kunming 5
Monmouth Junction 5
Princeton 5
Salvador 5
Toronto 5
Washington 5
Zhengzhou 5
Ankara 4
Ardabil 4
Asunción 4
Dhaka 4
Goiânia 4
Manfredonia 4
Mumbai 4
New Bedfont 4
Porto Alegre 4
Querétaro 4
Seoul 4
Wuhan 4
Amman 3
Totale 4.805
Salva come PNG Salva come JPEG
Nome #
Mast cells and angiogenesis in pancreatic ductal adenocarcinoma 233
Angiogenesis in adenosquamous cancer of pancreas 197
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 173
CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer 161
Fisiologia V Ed. 159
Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma 158
Targeting angiogenesis in biliary tract cancers: An open option 153
Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma 152
Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells 149
Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma 145
Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview 144
Bone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature review 144
Bone metastases in biliary cancers: A multicenter retrospective survey 143
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 140
Strategies to improve cancer immune checkpoint inhibitors efficacy, other than abscopal effect: A systematic review 138
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 134
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 134
Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma 133
Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance 132
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 129
Systematic review of irreversible electroporation role in management of locally advanced pancreatic cancer 127
Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma 124
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 121
Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets? 121
Long‐term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review 120
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib 116
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 111
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 110
Immunotherapy for colorectal cancer: where are we heading? 109
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 108
Molecular characterization of a long-term survivor double metastatic non-small cell lung cancer and pancreatic ductal adenocarcinoma treated with gefitinib in combination with gemcitabine plus nab-paclitaxel and mFOLFOX6 as first and second line therapy 106
The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy 105
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 103
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 102
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors 101
Management of patients with end-stage renal disease undergoing chemotherapy: Recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN) 99
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials 99
Bone metastases in hepatocellular carcinoma: an emerging issue 98
Cytotoxic t-lymphocyte antigen-4 in colorectal cancer: Another therapeutic side of capecitabine 98
COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients? 97
Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets 91
Basics and frontiers on pancreatic cancer for radiation oncology: Target delineation, SBRT, SIB technique, MRgRT, particle therapy, immunotherapy and clinical guidelines 88
Expression and characterization of a novel recombinant cytotoxin II from Naja naja oxiana venom: A potential treatment for breast cancer 87
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 86
Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection 84
null 81
Clinical practice guidelines for diagnosis, treatment and follow-up of exocrine pancreatic ductal adenocarcinoma: Evidence evaluation and recommendations by the italian association of medical oncology (AIOM) 81
Paraneoplastic focal segmental glomerulosclerosis in sarcomatoid renal cell cancer. 80
Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma: Could Surgery Represent a Therapeutic Option? 78
Immune system and bone microenvironment: rationale for targeted cancer therapies 76
null 67
NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer 66
A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery 66
The latest findings of PD-1/PD-L1 inhibitor application in gynecologic cancers 65
null 61
Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies 61
Is it Time for a Therapeutic Algorithm in Resected Pancreatic Ductal Adenocarcinoma? 47
Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis 46
On the Management of Drug Interactions in the Course of Concomitant Treatments for COVID-19 and Antineoplastic Agents 45
Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis 42
Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? 39
The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead 37
Identification of Common and Distinct Pathways in Inflammatory Bowel Disease and Colorectal Cancer: A Hypothesis Based on Weighted Gene Co-Expression Network Analysis 3
Totale 6.703
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.941
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.941
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021490 0 0 0 0 0 70 72 76 45 87 75 65
2021/2022509 42 19 13 15 20 45 17 30 37 46 68 157
2022/2023929 104 155 85 75 85 95 15 113 140 5 40 17
2023/2024324 19 59 15 28 33 95 7 9 3 7 3 46
2024/20251.210 53 11 85 51 47 111 103 107 44 79 197 322
2025/20261.416 405 115 168 281 326 121 0 0 0 0 0 0
Totale 6.703